Comparative Pharmacology
Head-to-head clinical analysis: BIPHETAMINE 7 5 versus RITALIN LA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIPHETAMINE 7 5 versus RITALIN LA.
BIPHETAMINE 7.5 vs RITALIN LA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Biphetamine 7.5 is a combination of amphetamine enantiomers (dextroamphetamine and levoamphetamine) that increase synaptic concentrations of dopamine and norepinephrine by inhibiting presynaptic reuptake and promoting release into the synaptic cleft.
Methylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
Initial 7.5 mg orally once daily in the morning, titrated based on response and tolerability. Maximum daily dose is 30 mg.
20-60 mg orally once daily in the morning; capsules may be swallowed whole or sprinkled on applesauce.
None Documented
None Documented
6-8 hours (amphetamine moiety), 10-13 hours (dextroamphetamine); clinical effects may outlast serum levels due to accumulation.
Methylphenidate: 3–4 hours (racemic); d-enantiomer: 6–8 hours; clinical context: duration of action 8–12 hours due to extended-release formulation
Renal: ~70-90% unchanged and as active metabolites; minor fecal elimination. Acidic urine (pH <5.6) increases excretion; alkaline urine (pH >7.0) decreases it.
Renal (78–97% as metabolites, primarily ritalinic acid, with <1% unchanged); fecal <2%
Category C
Category C
Central Nervous System Stimulant
Central Nervous System Stimulant